MetaVia Inc. — Director's Dealing 2016

Aug 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-10

Reporting Person: MATHIESEN JEFFREY S (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-10	Common Stock	C	3927	$6.7059	Acquired	3927	Direct
2016-08-10	Common Stock	P	4000	$10.00	Acquired	7927	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-10	8% Convertible Subordinated Promissory Note	$6.7059	C		Disposed		Common Stock (3927)	Direct

Footnotes

F1: The note was issued in the original principal amount of $25,000. The outstanding principal and $1,337 of accrued interest on the note automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.